Phase III Clinical Study of Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study on the Efficacy and Safety of Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease.
Sponsor: Beijing Tongren Hospital
Listed as NCT06879782, this PHASE3 trial focuses on Dry Eye Disease (DED) and remains actively recruiting participants. Sponsored by Beijing Tongren Hospital, it has been updated 2 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
2 versions recorded-
Sep 2025 — Present [monthly]
Recruiting PHASE3
-
Apr 2025 — Sep 2025 [monthly]
Recruiting PHASE3
First recorded
Mar 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Beijing Tongren Hospital
- Lunan Better Pharmaceutical Co., LTD.
For direct contact, visit the study record on ClinicalTrials.gov .